Gene Expression Regulation, Leukemic
"Gene Expression Regulation, Leukemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Concept/Terms
Gene Expression Regulation, Leukemic- Gene Expression Regulation, Leukemic
- Regulation of Gene Expression, Leukemic
- Regulation, Gene Expression, Leukemic
- Leukemic Gene Expression Regulation
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Leukemic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Leukemic".
This graph shows the total number of publications written about "Gene Expression Regulation, Leukemic" by people in Harvard Catalyst Profiles by year, and whether "Gene Expression Regulation, Leukemic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 1 | 2 |
| 1994 | 3 | 1 | 4 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 1 | 3 |
| 2003 | 4 | 4 | 8 |
| 2004 | 5 | 1 | 6 |
| 2005 | 6 | 6 | 12 |
| 2006 | 6 | 2 | 8 |
| 2007 | 7 | 8 | 15 |
| 2008 | 6 | 4 | 10 |
| 2009 | 2 | 6 | 8 |
| 2010 | 5 | 12 | 17 |
| 2011 | 6 | 8 | 14 |
| 2012 | 4 | 18 | 22 |
| 2013 | 8 | 9 | 17 |
| 2014 | 11 | 13 | 24 |
| 2015 | 14 | 10 | 24 |
| 2016 | 12 | 19 | 31 |
| 2017 | 9 | 13 | 22 |
| 2018 | 11 | 10 | 21 |
| 2019 | 11 | 13 | 24 |
| 2020 | 5 | 1 | 6 |
| 2021 | 11 | 12 | 23 |
| 2022 | 2 | 2 | 4 |
Below are the most recent publications written about "Gene Expression Regulation, Leukemic" by people in Profiles.
-
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. 2022 02 17; 139(7):1080-1097.
-
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022 02 10; 139(6):894-906.
-
ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood. 2022 01 20; 139(3):399-412.
-
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.
-
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. Am J Hematol. 2022 02 01; 97(2):E47-E51.
-
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884.
-
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 10 14; 138(15):1331-1344.
-
Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. Blood. 2021 10 14; 138(15):1345-1358.
-
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia. Cancer Res. 2021 11 15; 81(22):5733-5744.
-
ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis. Leukemia. 2022 02; 36(2):549-554.